CYTK Stock Analysis: Buy, Sell, or Hold?
CYTK - Cytokinetics Inc.
$74.13
0.68 (0.93%)
▲
5d:
-3.43%
30d:
-7.75%
90d:
-5.73%
HOLD
MODERATE Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 7, 2026 at $76.76 · last confirmed Aug 14, 2026
Strength: 7.9/10
Get Alerted When CYTK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CYTK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CYTK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CYTK is currently trading at $74.13, which is considered oversold relative to its 30-day fair value range of $76.85 to $83.46.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is currently testing key support at $72.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CYTK scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $108.85 (+46.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CYTK is in a strong uptrend. The price is currently testing key support at $72.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CYTK scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $108.85 (+46.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$76.85 -
$83.46
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
Protect Your Profits
Holding CYTK? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 46.8% below Wall St target ($108.85)
Trading Range Analysis
30-Day Trading Range
$76.85 -
$83.46
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$72.12
Resistance Level
$81.77
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.76
Wall Street Target
$108.85
(+46.8%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: August 16, 2026 3:10 AM ET
Data refreshes hourly during market hours. Next update: 4:10 AM
Data refreshes hourly during market hours. Next update: 4:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYTK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Fady Ibraham Malik
SELL
3500 shares
2026-04-21
Robert I Blum
SELL
7500 shares
2026-04-15
Andrew Callos
SELL
7449 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$431 | 33 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 42 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 29 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 45 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
Advanced CYTK Option Strategies
Professional options setups generated by AI based on today's CYTK price and gamma walls.
